Ventricular assist devices

Current Opinion in Anaesthesiology

Volumn 16, Issue 1, 2003, Pages 33-43

  Collard, Edith ^a,b   Van Dyck, Michel J ^a,c   Jacquet, Luc M ^a,c  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^b UNIVERSITY HOSPITAL OF MONT GODINNE   (Belgium)

^c CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

Heart failure; Heart transplantation; Ventricular assist device

Indexed keywords

ASSISTED CIRCULATION; BLEEDING; BLOOD PUMP; CONGESTIVE HEART FAILURE; DEVICE FAILURE; DEVICE INFECTION; ELECTROPHYSIOLOGY; GIANT CELL; HEART ASSIST DEVICE; HEART FAILURE; HEART FUNCTION; HEART STROKE VOLUME; HEART TRANSPLANTATION; HEMODYNAMICS; IMMUNE DEFICIENCY; IMPLANT; INFECTION; MOLECULAR BIOLOGY; MOLECULAR MODEL; MYOCARDITIS; PRIORITY JOURNAL; PULSATILE FLOW; QUALITY OF LIFE; REVIEW; SEPSIS; THROMBOEMBOLISM; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TREATMENT INDICATION;

EID: 0037323036     PISSN: 09527907     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001503-200302000-00006     Document Type: Review

References (58)

1. Gradaus R, Kerber S, Bocker D, et al. Therapeutic options and heart failure survival score predictability in an academic heart failure center: an analysis of 120 consecutive patients during a 1-year period. Eur J Heart Fail 2002; 4:207-214.
2. Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345:1435-1443. •• The multicentric REMATCH study: a landmark paper that compares optimal medical management with the placement of a LVAD as destination therapy for patients with end-stage cardiac failure and ineligible for HTx.
3. Baughman KL. B-Type natriuretic peptide: a window to the heart. N Engl J Med 2002; 347:158-159. • The usefulness of B-type natriuretic peptide levels in the diagnosis, severity, prognosis and therapy of congestive heart failure.
4. Birks EJ, Latif N, Owen V, et al. Quantitative myocardial cytokine expression and activation of the apoptotic pathway in patients who require left ventricular assist devices. Circulation 2001; 104 (12 Suppl 1): 1233-1240. • The authors studied molecular mechanisms which could contribute to decompensation of patients with advanced heart failure, as well as having therapeutic implications, but also influence the timing of LVAD insertion.
5. Fogoros RN, Elson JJ, Bonnet CA, et al. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol 1990; 16:381-386.
6. Molhoek SG, Bax JJ, van Erven L, et al. Effectiveness of resynchronization therapy in patients with end-stage heart failure, Am J Cardiol 2002; 90:379-383.
7. Meyns B, Sergeant P, Herijgers P, et al. Bridging procedures to heart transplantation, World J Surg 2002; 26:212-217.
8. Thiele H, Lauer B, Hambrecht R, et al. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 2001; 104:2917-2922.
9. Arabia FA. Update on the total artificial heart. J Card Surg 2001; 16:222-227.
10. Reichenbach SH, Farrar DJ, Hill JD. A versatile intracorporeal ventricular assist device based on the Thoratee VAD system. Ann Thorae Surg 2001; 71 (3 Suppl):S171-S175; discussion S183-S184.
11. Wieselthaler GM, Schima H, Hiesmayr M, et al. First clinical experience with the DeBakey VAD continuous-axial-flow pump for bridge to transplantation. Circulation 2000; 101:356-359.
12. Wieselthaler GM, Schima H, Lassnigg AM, et al. Lessons learned from the first clinical implants of the DeBakey ventricular assist device axial pump: a single center report, Ann Thorac Surg 2001; 71 (3 Suppl):S139-S143.
13. Agati S, Bruschi G, Russo C, et al. First successful Italian clinical experience with DeBakey VAD. J Heart Lung Transplant 2001; 20:914-917.
14. Griffith BP, Kormos RL, Borovetz HS, et al. HeartMate II left ventricular assist system: from concept to first clinical use. Ann Thorac Surg 2001; 71 (3 Suppl):S115-S120.
15. Cooley DA. Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system. Circulation 2002; 105:2808-2809.
16. Frazier OH, Myers TJ, Gregorie ID, et al. Initial clinical experience with the Jarvik 2000 implantable axial-flow left ventricular assist system. Circulation 2002; 105:2855-2860. • The first clinical experience with the Jarvik 2000 implantable axial-flow LVAD in 10 heart transplant candidates.
17. Noon GP, Morley DL, Irwin S, et al. Clinical experience with the MicroMed DeBakey ventricular assist device. Ann Thorac Surg 2001; 71 (3 Suppl):S133-S138.
18. Potapov EV, Loebe M, Abdul-Khaliq H, et al. Postoperative course of S-100B protein and neuron-specific enolase in patients after implantation of continuous and pulsatile flow LVADs. J Heart Lung Transplant 2001; 20:1310-1316.
19. Nojiri C, Kijima T, Maekawa J, et al. Development status of Terumo implantable left ventricular assist system. Artif Organs 2001; 25:411-413.
20. Saito S, Westaby S, Piggott D, et al. Reliable long-term non-pulsatile circulatory support without anticoagulation. Eur J Cardiothorac Surg 2001; 19:678-683. • An animal study of a novel nonpulsatile centrifugal pump with a magnetically suspended impeller which is promising in terms of mechanical reliability and nonthrombogenicity.
21. Nonaka K, Linneweber J, Ichikawa S, et al. Development of the Baylor Gyro permanently implantable centrifugal blood pump as a biventricular assist device, Artif Organs 2001; 25:675-682.
22. Holman WL, Davies JE, Rayburn BK, et al. Treatment of end-stage heart disease with outpatient ventricular assist devices. Ann Thorac Surg 2002; 73:1489-1493; discussion 1493-1494.
23. Davies RA, Veinot JP, Smith S, et al. Giant cell myocarditis: clinical presentation, bridge to transplantation with mechanical circulatory support, and long-term outcome. J Heart Lung Transplant 2002; 21:674-679.
24. McGovern PC, Chambers S, Blumberg EA, et al. Successful explantation of a ventricular assist device following fulminant influenza type A-associated myocarditis. J Heart Lung Transplant 2002; 21:290-293.
25. Minev PA, El-Banayosy A, Minami K, et al. Differential indication for mechanical circulatory support following heart transplantation. Intensive Care Med 2001; 27:1321-1327.
26. Ko WJ, Lin CY, Chen RJ, et al. Extracorporeal membrane oxygenation support for adult postcardiotomy cardiogenic shock. Ann Thorac Surg 2002; 73:538-545.
27. Chen YS, Ko WJ, Lin FY, et al. Preliminary result of an algorithm to select proper ventricular assist devices for high-risk patients with extracorporeal membrane oxygenation support, J Heart Lung Transplant 2001; 20:850-857.
28. Masai T, Sawa Y, Ohtake S, et al. Hepatic dysfunction after left ventricular mechanical assist in patients with end-stage heart failure: role of inflammatory response and hepatic microcirculation. Ann Thorac Surg 2002; 73:549-555.
29. Young JB. Healing the heart with ventricular assist device therapy: mechanisms of cardiac recovery. Ann Thorac Surg 2001; 71:S210-S219. •• A good review on pathophysiology of heart failure and how VADs may promote myocardial recovery in selected patients with advanced heart failure from clinical and experimental standpoints.
30. Kumpati GS, McCarthy PM, Hoercher KJ, Left ventricular assist device bridge to recovery: a review of the current status. Ann Thorac Surg 2001; 71:S103-S108. • This paper focuses on bridge-to-recovery in the settings of myocarditis and dilated cardiomyopathy with a review of the mechanisms of recovery during LVAD support and suggests options to increase the chance of success.
31. Hetzer R, Muller JH, Weng Y, et al. Bridging-to-recovery. Ann Thorac Surg 2001; 71 (3 Suppl):S109-S113
32. Tisol WB, Mueller DK, Hoy FB, et al. Ventricular assist device use with mechanical heart valves: an outcome series and literature review. Ann Thorae Surg 2001; 72:2051-2054; discussion 2055.
33. Grabellus F, Levkau B, Sokoll A, et al. Reversible activation of nuclear factor-kappaB in human end-stage heart failure after left ventricular mechanical support. Cardiovase Res 2002; 53:124-130.
34. Li YY, Feng Y, McTiernan CF, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001; 104:1147-1152. • Regression of the remodelling of the failing heart after mechanical unloading could be due to changes in the extracellular matrix.
35. Mann DL, Taegtmeyer H. Dynamic regulation of the extracellular matrix after mechanical unloading of the failing human heart: recovering the missing link in left ventricular remodeling. Circulation 2001; 104:1089-1091. • The authors discuss the regulation of the extracellular matrix in the failing heart and emphasize the importance of the study by Li and colleagues on the potential role of the reorganization of the collagen network in the regression of the left ventricular remodelling.
36. Barbone A, Holmes JW, Heerdt PM, et al. Comparison of right and left ventricular responses to left ventricular assist device support in patients with severe heart failure: a primary role of mechanical unloading underlying reverse remodeling, Circulation 2001; 104:670-675.
37. Harding JD, Piacentino V III, Gaughan JP, et al. Electrophysiological alterations after mechanical circulatory support in patients with advanced cardiac failure. Circulation 2001; 104:1241-1247. • This paper describes the occurrence of electrophysiological remodelling after sustained LVAD support and demonstrates parallel shifts in the QT interval and myocardial repolarization.
38. Maybaum S, Epstein S, Beniaminovitz A, et al. Partial loading of the left ventricle during mechanical assist device support is associated with improved myocardial function, blood flow and metabolism and increased exercise capacity. J Heart Lung Transplant 2002; 21:446-454. • This study suggests that partial loading of the left ventricle during LVAD support could be beneficial.
39. Richenbacher WE. Recovery of myocardial function with long-term ventricular assist device support. ASAIO J 2001; 47:586-587. •• An editorial that poses pertinent questions about the possible myocardial recovery and the eventual weaning of VADs.
40. Milting H, EL Banayosy A, Kassner A, et al. The time course of natriuretic hormones as plasma markers of myocardial recovery in heart transplant candidates during ventricutar assist device support reveals differences among device types. J Heart Lung Transplant 2001; 20:949-955.
41. Slaughter MS, Silver MA, Farrar DJ, et al. A new method of monitoring recovery and weaning the Thoratec left ventricular assist device. Ann Thorac Surg 2001; 71:215-218.
42. Helman DN, Maybaum SW, Morales DLS, et al. Recurrent remodeling after ventricular assistance: is long-term myocardial recovery attainable? Ann Thorac Surg 2000; 70:1255-1258.
43. Kavarana MN, Pessin-Minsley MS, Urtecho J, et al. Right ventricular dysfunction and organ failure in left ventricular assist device recipients: a continuing problem. Ann Thorac Surg 2002; 73:745-750; invited commentary by McCarthy 750. A retrospective study identifying risks factors for right ventricular dysfunction in patients receiving left ventricular assist device. Suggestions of McCarthy for the prevention and treatment of this frequent complication.
44. Loebe M, Potapov E, Sodian R, et al. A safe and simple method of preserving right ventricular function during implantation of a left ventricular assist device. J Thorac Cardiovasc Surg 2001; 122:1043.
45. Grady KL, Meyer P, Mattea A, et al. Improvement in quality of life outcomes 2 weeks after left ventricular assist device implantation. J Heart Lung Transplant 2001; 20:657-669.
46. Richenbacher WE, Seemuth SC. Hospital discharge for the ventricular assist device patient: historical perspective and description of a successful program. ASAIO J 2001; 47:590-595. • How to prepare the VAD patient for the transition from hospital to home.
47. Seemuth SC, Richenbacher WE. Education of the ventricular assist device patient's community services. ASAIO J 2001; 47:596-601.
48. Mettauer B, Geny B, Lonsdorfer-Wolf E, et al. Exercise training with a heart device: a hemodynamic, metabolic, and hormonal study. Med Sci Sports Exerc 2001; 33:2-8.
49. Long JW. Advanced mechanical circulatory support with the HeartMate left ventricular assist device in the year 2000. Ann Thorac Surg 2001; 71:S176-S182.
50. Tittle SL, Mandapati D, Kopf GS, Elefteriades JA. Alternate technique for implantation of left ventricular assist system: left thoracotomy for reoperative cases. Ann Thorac Surg 2002; 73:994-996.
51. Mets B. Anesthesia for left ventricular assist device placement. J Cardiothorac Vasc Anesth 2000; 14:316-326.
52. Stone ME, Soong W, Krol M, Reich DL. The anesthetic considerations in patients with ventricular assist devices presenting for noncardiac surgery: a review of eight cases. Anesth Analg 2002; 95:42-49. •• For the noncardiac anaesthesiologists, a systematic approach for the anaesthetic management of VAD supported patients.
53. Schmid C, Wilhelm M, Dietl KH, et al. Noncardiac surgery in patients with left ventricular assist devices. Surgery 2001; 129:440-444.
54. Scalia GM, McCarthy PM, Savage RM, et al. Clinical utility of echocardiography in the management of implantable ventricular assist devices. J Am Soc Echocardiogr 2000; 13:754-763.
55. Ferns J, Dowling R, Bhat G. Evaluation of a patient with left ventricular assist device dysfunction. ASAIO J 2001; 47:696-698.
56. Ankersmit HJ, Wieselthaler G, Moser B, et al. Transitory immunologic response after implantation of the DeBakey VAD continuous-axial-flow pump. J Thorac Cardiovasc Surg 2002; 123:557-561.
57. Gordon SM, Schmitt SK, Jacobs M, et al. Nosocomial bloodstream infections in patients with implantable left ventricular assist devices. Ann Thorac Surg 2001; 72:725-730.
58. Russo C, De Biase AM, Bruschi G, et al. Successful intraventricular thrombolysis during ventricular assist device support. Ann Thorac Surg 2002; 73:1628-1629.